AERIAL Trial: Antiplatelet Therapy in Heart Transplantation
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorOttawa Heart Institute Research Corporation
Cardiac allograft vasculopathy is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. The research team is investigating whether early antiplatelet therapy post heart transplant can prevent the development of CAV. This study will determine the feasibility of a large multicenter randomized placebo-controlled trial to answer this question.
Heart transplant
Age ≥18 years
Able to provide informed consent
Allergy or known intolerance to aspirin
Allergy or known intolerance to clopidogrel
Intracranial hemorrhage ≤14 days
Bleeding disorder
Ottawa Heart Institute Research Corporation
Lead sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator